Q-omics provides the consensus-scored SREK1IP1P1 profile across patient tissues and cancer cell-line models. SREK1IP1P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SREK1IP1P1 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, SREK1IP1P1 RNA expression shows 6,092 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, COAD, and THYM as cancer lineages where SREK1IP1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SREK1IP1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SREK1IP1P1 survival associations across molecular data types. SREK1IP1P1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SREK1IP1P1 RNA expression–survival associations across cancer types. High SREK1IP1P1 expression shows unfavorable associations in LUAD, UVM, LIHC and ACC, but favorable associations in UCEC and BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for SREK1IP1P1 RNA expression.
This table summarizes SREK1IP1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SREK1IP1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SREK1IP1P1 shows higher tumor expression in COAD, READ, KIRC, LUAD, CHOL and LIHC. The COAD box plot shows higher SREK1IP1P1 RNA expression in tumor versus normal tissue (log2 FC = +0.116, t-test p = .015).
This table shows molecular features associated with SREK1IP1P1 in patient tissues and cancer cell lines. In patient samples, SREK1IP1P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
